Navigation Links
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Date:7/6/2008

atients with advanced NSCLC were randomized to the comparator arm; 191 were randomized to the OPAXIO arm with a dosage of 175 mg/m^2, and 96 were randomized to the OPAXIO arm at a dosage of 235 mg/m^2. The OPAXIO dose was reduced to 175 mg/m^2 after 96 patients had been treated, because the Data Monitoring Committee noted an increase in deaths associated with neutropenia in patients who had received the 235 mg/m^2 dosage. The following data refers to those patients treated at the OPAXIO dose of 175 mg/m^2. The median number of cycles administered was 4, with a median of 3.5 in the control arm. A total of 754 cycles of OPAXIO were administered, and 652 cycles were administered in the comparator arm. More patients in the OPAXIO arm received 6 cycles of treatment (38 percent versus 23 percent; p = 0.002). Progressive disease was the most common reason for not completing 6 cycles (55 percent in the OPAXIO arm and 59 percent in the comparator arm). Fewer OPAXIO patients (12 percent) discontinued treatment as a result of adverse events, compared to 17 percent of patients in the control arm. Survival, time to progression (TTP), and response rates were similar in both arms. Median overall survival was 7.3 months in the OPAXIO arm and 6.6 months in the control arm. The estimated 1-year survival rate was the same in both arms (26 percent), and the approximate 2-year survival rate was numerically higher in the OPAXIO arm (15 percent) than the comparator arm (10 percent). There was a lower requirement for red blood cell transfusions (p = 0.001), erythropoietin use (p = 0.014), myeloid growth factors (p = 0.032), and new narcotic analgesics (p = 0.034) in the OPAXIO arm when compared to the control arm. No significant differences were evident in quality of life based on FACT-LCS evaluations between the two arms. OPAXIO patients experienced fewer hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. Neuropathy occurred more frequently in the OPAXIO arm compared
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
2. Genzyme and Isis Complete Licensing of Mipomersen
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
(Date:2/27/2015)... Mass. and JERUSALEM , ... biopharma company developing octreotide capsules, its lead product for ... a $70 million Series E financing round. Participants in ... Sofinnova Ventures, and an undisclosed blue chip public investment ... Capital, 7 Med Health Ventures, Abingworth and ARCH Venture ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... 2011 - Vention Medical, a leading full-service ... acquisition of ANSAmed, Ireland,s premier  provider of ... and multi-lumen extrusion capabilities, and catheter design, ... acquisition of ANSAmed will expand Vention Medical,s ...
... 26, 2011 Varian Medical Systems (NYSE: VAR ... with Bank of America, N.A. to repurchase $250 million of ... the company amended its revolving credit facility with Bank of ... to $300 million. Under the accelerated repurchase agreement, ...
Cached Medicine Technology:Vention Medical Acquires ANSAmed 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... Santa Cruz, california (PRWEB) February 28, 2015 ... an ever growing number of practicing physicians as a way ... experience, training or education regarding Cannabis as medicine. Since the ... have been very few resources available to licensed physicians ... treatment to a patient. Dr. Deborah Malka in Santa ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, ... pleased to announce the development of Q-Suite 5.9. Building ... of Q-Suite, this new version will include enhancements to ... features to the leading edge call center software. General ... add features to enhance security and protection. Administrators will ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Company) (NYSE: BDX ), a global medical technology company,announced today that ... 2008 Annual Credit Suisse Healthcare Conference ... pm ET, Lazard Capital Markets 5th Annual ... 10:55 a.m. ET, A live webcast of BD,s ...
... (human papillomavirus) vaccines and the validation of a simple oral ... studies by a Johns Hopkins Kimmel Cancer Center investigator. , ... identify HPV infection as the cause of certain oral cancers ... risk factor for these cancers, reports her latest work in ...
... Taking Medications for Blood Pressure, Cholesterol, ... Asthma, ADD/ADHD, Depression and Diabetes, ST. LOUIS, Nov. 3 ... type 2 diabetes medications between 2002 and,2005, with girls between ... One likely cause: Obesity, which is closely associated with type,2 ...
... Declared, ACTON, Mass., Nov. 3 Psychemedics Corporation,(Nasdaq: ... for the,period ended September 30, 2008. The Company also ... shareholders of record as of,December 3, 2008 to be ... 49th consecutive quarterly dividend., The Company,s third quarter ...
... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... Conference on November 11, 2008. The Company will be ... and Christopher,M. Hix, Vice President and Chief Financial Officer., ... CST, at,the Four Seasons Hotel in Chicago, Illinois. It ...
... Leading Cause of Death in U.S., SWANTON, Vt., ... Month, to help raise awareness about Chronic,Obstructive Pulmonary Disease ... will be making downloadable,tips available to COPD patients on ... November newsletter and blogs to raising awareness,about this 4th ...
Cached Medicine News:Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 3Health News:Tweens and Teens Double Use of Diabetes Drugs 2Health News:Tweens and Teens Double Use of Diabetes Drugs 3Health News:Tweens and Teens Double Use of Diabetes Drugs 4Health News:Psychemedics Corporation Announces Third Quarter Results 2Health News:Psychemedics Corporation Announces Third Quarter Results 3Health News:Psychemedics Corporation Announces Third Quarter Results 4Health News:Psychemedics Corporation Announces Third Quarter Results 5Health News:AllerAir Dedicates November to COPD Awareness Month 2
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medicine Products: